Early Access — free while we kick the tires
EdgarHawk

Von Koch Thomas

10% Owner

10% Owner
2 filings analyzed · 1 company · Latest 2025-07-25

Companies

Company Buys Sells Direction
DiaMedica Therapeutics Inc. DMAC 2 0 Net buying

Activity

July 2025
high
Buy
2,857,142 shares
$9,999,997
Significance 6/10

10% owner Von Koch Thomas purchased 2,857,142 shares of DMAC for $10.0M on 2025-07-23; cluster buy pattern with 2 other insiders.

Von Koch Thomas, a 10% owner, deployed $9,999,997.00 ($10.0M) to acquire 2,857,142 shares at $3.50, expanding holdings by 51.7% to 8,383,577 shares. This represents a significant capital commitment at a price 30.7% below the current market level of $5.05 and 47.2% below the 52-week high of $6.65. The timing context is mixed: his prior buy at DMAC on 2024-06-28 at this ticker delivered +45.6% in 30 days and +72.0% in 90 days, whereas his 2023-06-23 buy produced only +6.2% at 30 days and -11.8% at 90 days, reflecting inconsistent near-term outcomes on this security. The transaction also coincides with a cluster pattern—2 other insiders bought within the past 14 days—which may indicate coordinated or reactive signaling, though the company remains unprofitable with net income of $-7,707,000.00 on quarterly revenue of $500,000.00. Stock has risen 27.8% over 30 days and 25.0% over 90 days, suggesting momentum may predate or follow this filing's disclosure.

July 2024
high
Buy
1,200,000 shares
$3,000,000
Significance 6/10

10% owner Von Koch Thomas buys 1,200,000 shares of DMAC at $2.50 (June 28), increasing stake to 5,526,435 shares (+27.7%)

Von Koch Thomas, a 10% owner, deployed $3,000,000 to purchase 1,200,000 shares at $2.50 on 2024-06-28, expanding his holdings by 27.7% to 5,526,435 shares. The transaction occurs in a company with negative fundamentals—net income of $-5,151,000 and quarterly revenue of $500,000—that is unprofitable on a full-year basis, suggesting the purchase is not driven by strong operational momentum. At the current price of $2.95, the stock has recovered 1.7% over 30 days and 8.1% over 90 days, but remains 33.0% below its 52-week high of $4.40. Notably, his prior buy at this ticker on 2023-06-23 was poorly timed, showing a 90-day return of -11.8%, indicating a pattern of purchases that did not precede stock appreciation. This repeat accumulation at a depressed valuation deserves attention to understand whether the insider believes a turnaround is imminent or whether market conditions have shifted since the prior purchase.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access